Advertisement

Statin Therapy and Intensity: Prognosis in Patients with Myocardial Injury

  • Erik Kadesjö
    Correspondence
    Requests for reprints should be addressed to Erik Kadesjö, MD, Department of Emergency and Reparative Medicine, Karolinska University Hospital, Huddinge, SE-141 86 Stockholm, Sweden.
    Affiliations
    Department of Medicine, Karolinska Institutet, Solna, Stockholm, Sweden

    Department of Emergency and Reparative Medicine, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Search for articles by this author
  • Andreas Roos
    Affiliations
    Department of Medicine, Karolinska Institutet, Solna, Stockholm, Sweden

    Department of Emergency and Reparative Medicine, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Search for articles by this author
  • Anwar J. Siddiqui
    Affiliations
    Department of Medicine, Karolinska Institutet, Solna, Stockholm, Sweden

    Department of Emergency and Reparative Medicine, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Search for articles by this author
  • Ulrik Sartipy
    Affiliations
    Department of Cardiothoracic Surgery, Karolinska University Hospital, Stockholm, Sweden

    Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
    Search for articles by this author
  • Author Footnotes
    ⁎ Deceased June 5, 2021.
    Martin J. Holzmann
    Footnotes
    ⁎ Deceased June 5, 2021.
    Affiliations
    Department of Medicine, Karolinska Institutet, Solna, Stockholm, Sweden

    Department of Emergency and Reparative Medicine, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Search for articles by this author
  • Author Footnotes
    ⁎ Deceased June 5, 2021.

      Abstract

      Background

      No guideline-directed pharmacological therapy has been established for patients with myocardial injury without type 1 myocardial infarction. We investigated the impact of statin treatment in patients with myocardial injury.

      Methods

      Patients with myocardial injury (nonischemic acute and chronic myocardial injury), type 2 myocardial infarction, and type 1 myocardial infarction with at least 1 emergency department visit for chest pain from 2011 to 2014 were included. Dispensed prescriptions of all types of statins with dosage within 180 days from the index visit were collected. In total, 2054 patients were divided into 3 groups: 1) acute myocardial injury (type 2 myocardial infarction, acute nonischemic myocardial injury), 2) chronic myocardial injury, and 3) type 1 myocardial infarction. We estimated the adjusted hazard ratio with 95% confidence interval for death with low- (reference), moderate-, and high-intensity statin therapy.

      Results

      The mean follow-up was 4.2 ± 1.8 years. Only 13% of patients with acute and chronic myocardial injury and 30% with type 1 myocardial infarction were treated with high-intensity statins. Adjusted mortality rates were higher in patients with acute and chronic myocardial injury than in those with type 1 myocardial infarction across all statin intensity categories. In patients with type 1 myocardial infarction, the adjusted mortality risk was 20% (hazard ratio, 0.80; 95% confidence interval, 0.36-1.77) lower in patients with high-intensity therapy. Point estimates in the adjusted models indicated similar associations between statin intensity and mortality risk in patients with acute and chronic myocardial injury.

      Conclusion

      Patients with myocardial injury may benefit from high-intensity statin treatment, but the associations were not statistically significant when adjusting for confounders.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kadesjö E
        • Roos A
        • Siddiqui A
        • et al.
        Acute versus chronic myocardial injury and long-term outcomes.
        Heart. 2019; 105: 1905-1912https://doi.org/10.1136/heartjnl-2019-315036
        • Sandoval Y
        • Smith SW
        • Sexter A
        • Thordsen SE
        • et al.
        Type 1 and 2 myocardial infarction and myocardial injury: clinical transition to high-sensitivity cardiac troponin I.
        Am J Med. 2017; 130: 1431-1439.e4https://doi.org/10.1016/j.amjmed.2017.05.049
        • Chapman AR
        • Adamson PD
        • Shah ASV
        • et al.
        High-sensitivity cardiac troponin and the universal definition of myocardial infarction.
        Circulation. 2020; 141: 161-171https://doi.org/10.1161/CIRCULATIONAHA.119.042960
        • Thygesen K
        • Alpert JS
        • Jaffe AS
        • et al.
        Fourth universal definition of myocardial infarction (2018).
        J Am Coll Cardiol. 2018; 72: 2231-2264https://doi.org/10.1016/j.jacc.2018.08.1038
        • DeFilippis AP
        • Chapman AR
        • Mills NL
        • et al.
        Assessment and treatment of patients with type 2 myocardial infarction and acute nonischemic myocardial injury.
        Circulation. 2019; 140: 1661-1678https://doi.org/10.1161/CIRCULATIONAHA.119.040631
        • Lambrecht S
        • Sarkisian L
        • Saaby L
        • et al.
        Different causes of death in patients with myocardial infarction type 1, type 2, and myocardial Injury.
        Am J Med. 2018; 131: 548-554https://doi.org/10.1016/j.amjmed.2017.11.043
        • Cannon CP
        • Braunwald E
        • McCabe CH
        • et al.
        Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
        N Engl J Med. 2004; 350: 1495-1504https://doi.org/10.1056/NEJMoa040583
        • LaRosa JC
        • Grundy SM
        • Waters DD
        • et al.
        Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
        N Engl J Med. 2005; 352: 1425-1435https://doi.org/10.1056/NEJMoa050461
        • Koren MJ
        • Hunninghake DB.
        Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.
        J Am Coll Cardiol. 2004; 44: 1772-1779https://doi.org/10.1016/j.jacc.2004.07.053
        • Baigent C
        • Blackwell L
        • Emberson J
        • et al.
        Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials.
        Lancet. 2010; 376: 1670-1681https://doi.org/10.1016/S0140-6736(10)61350-5
        • von Elm E
        • Altman DG
        • Egger M
        • et al.
        The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.
        J Clin Epidemiol. 2008; 61: 344-349https://doi.org/10.1016/j.jclinepi.2007.11.008
        • Roos A
        • Bandstein N
        • Lundbäck M
        • et al.
        Stable high-sensitivity cardiac troponin T levels and outcomes in patients with chest pain.
        J Am Coll Cardiol. 2017; 70: 2226-2236https://doi.org/10.1016/j.jacc.2017.08.064
        • Roffi M
        • Patrono C
        • Collet J-P
        • et al.
        2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.
        Eur Heart J. 2016; 37: 267-315https://doi.org/10.1093/eurheartj/ehv320
        • Quan H
        • Li B
        • Couris CM
        • et al.
        Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries.
        Am J Epidemiol. 2011; 173: 676-682https://doi.org/10.1093/aje/kwq433
        • Charlson ME
        • Pompei P
        • Ales KL
        • MacKenzie CR.
        A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
        J Chronic Dis. 1987; 40: 373-383https://doi.org/10.1016/0021-9681(87)90171-8
        • Radovanovic D
        • Seifert B
        • Urban P
        • et al.
        Validity of Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome. Insights from the nationwide AMIS Plus registry 2002-2012.
        Heart. 2014; 100: 288-294https://doi.org/10.1136/heartjnl-2013-304588
        • Nagele P.
        A simplified proposal to redefine acute myocardial infarction versus acute myocardial injury.
        Circulation. 2020; 141: 1431-1433https://doi.org/10.1161/CIRCULATIONAHA.119.044996
        • Stone NJ
        • Robinson JG
        • Lichtenstein AH
        • et al.
        2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines.
        Circulation. 2014; 129 (Suppl 1): 1-45https://doi.org/10.1161/01.cir.0000437738.63853.7a
        • Brooke HL
        • Talbäck M
        • Hörnblad J
        • et al.
        The Swedish cause of death register.
        Eur J Epidemiol. 2017; 32: 765-773https://doi.org/10.1007/s10654-017-0316-1
        • Ludvigsson JF
        • Andersson E
        • Ekbom A
        • et al.
        External review and validation of the Swedish national inpatient register.
        BMC Public Health. 2011; 11: 450https://doi.org/10.1186/1471-2458-11-450
        • Sidebottom AC
        • Vacquier MC
        • Jensen JC
        • et al.
        Trends in prevalence of guideline-based use of lipid-lowering therapy in a large health system.
        Clin Cardiol. 2020; 43: 560-567https://doi.org/10.1002/clc.23347
        • Allahyari A
        • Jernberg T
        • Lautsch D
        • et al.
        Low-density lipoprotein-cholesterol target attainment according to the 2011 and 2016 ESC/EAS dyslipidaemia guidelines in patients with a recent myocardial infarction: nationwide cohort study, 2013-17.
        Eur Heart J Qual Care Clin Outcomes. 2021; 7: 59-67https://doi.org/10.1093/ehjqcco/qcaa016
        • White HD
        • Steg PG
        • Szarek M
        • et al.
        Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial.
        Eur Heart J. 2019; 40: 2801-2809https://doi.org/10.1093/eurheartj/ehz299
        • Mills NL
        • Zhang R
        • Strachan FE
        • et al.
        High-sensitivity cardiac troponin, statin therapy, and risk of coronary heart disease.
        J Am Coll Cardiol. 2016; 68: 2719-2728https://doi.org/10.1016/j.jacc.2016.10.020
        • Wang KW
        • Feng C
        • Wu YF
        • et al.
        Statin pretreatment might be associated with decreased myocardial injury after ischemic stroke.
        J Stroke Cerebrovasc Dis. 2020; 29104697https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104697
        • Baigent C
        • Keech A
        • Kearney PM
        • et al.
        Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins.
        Lancet. 2005; 366: 1267-1278https://doi.org/10.1016/S0140-6736(05)67394-1
        • Chou R
        • Dana T
        • Blazina I
        • et al.
        Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US preventive services task force.
        JAMA. 2016; 316: 2008-2024https://doi.org/10.1001/jama.2015.15629
        • Catapano AL
        • Graham I
        • De Backer G
        • et al.
        2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.
        Eur Heart J. 2016; 37: 2999-3058https://doi.org/10.1093/eurheartj/ehw272
        • Rodriguez F
        • Maron DJ
        • Knowles JW
        • et al.
        Association between intensity of statin therapy and mortality in patients with atherosclerotic cardiovascular disease.
        JAMA Cardiol. 2017; 2: 47-54https://doi.org/10.1001/jamacardio.2016.4052
        • Chapman AR
        • Shah ASV
        • Lee KK
        • et al.
        Long-term outcomes in patients with type 2 myocardial infarction and myocardial injury.
        Circulation. 2018; 137: 1236-1245https://doi.org/10.1161/CIRCULATIONAHA.117.031806
        • Putot A
        • Derrida SB
        • Zeller M
        • et al.
        Short-term prognosis of myocardial injury, type 1, and type 2 myocardial infarction in the emergency unit.
        Am J Med. 2018; 131: 1209-1219https://doi.org/10.1016/j.amjmed.2018.04.032
        • Cediel G
        • Gonzalez-del-Hoyo M
        • Carrasquer A
        • et al.
        Outcomes with type 2 myocardial infarction compared with non-ischaemic myocardial injury.
        Heart. 2017; 103: 616-622https://doi.org/10.1136/heartjnl-2016-310243